IMAB Projected Dividend Yield
ADS (Sponsored)/I-Mab ( NASDAQ : IMAB )I-Mab is a holding company. Through its subsidiaries, Co. is primarily engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries. Co.'s drug pipeline includes: Felzartamab (TJ202), which is a monoclonal antibody directed against CD38; Eftansomatropin alfa (TJ101), which is a recombinant human growth hormone being developed as a therapy for growth hormone deficiency; Lemzoparlimab (TJC4), which is a CD47 monoclonal antibody discovered and developed internally by Co. for cancer immunotherapy; and Uliledlimab (TJD5), which is an inhibitory antibody against human CD73. 21 YEAR PERFORMANCE RESULTS |
IMAB Dividend History Detail IMAB Dividend News IMAB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |